SEARCH

SEARCH BY CITATION

References

  • Bakker, A.B., Van Den Oudenrijn, S., Bakker, A.Q., Feller, N., Van Meijer, M., Bia, J.A., Jongeneelen, M.A., Visser, T.J., Bijl, N., Geuijen, C.A., Marissen, W.E., Radosevic, K., Throsby, M., Schuurhuis, G.J., Ossenkoppele, G.J., De Kruif, J., Goudsmit, J. & Kruisbeek, A.M. (2004) C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Research, 64, 84438450.
  • Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., Einsele, H., Brandl, C., Wolf, A., Kirchinger, P., Klappers, P., Schmidt, M., Riethmuller, G., Reinhardt, C., Baeuerle, P.A. & Kufer, P. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science, 321, 974977.
  • Barth, S., Huhn, M., Matthey, B., Tawadros, S., Schnell, R., Schinkothe, T., Diehl, V. & Engert, A. (2000) Ki-4(scFv)-ETA’, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood, 95, 39093914.
  • Benedict, C.A., MacKrell, A.J. & Anderson, W.F. (1997) Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. Journal of Immunological Methods, 201, 223231.
  • Bonnet, D. & Dick, J.E. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730737.
  • Bruenke, J., Fischer, B., Barbin, K., Schreiter, K., Wachter, Y., Mahr, K., Titgemeyer, F., Niederweis, M., Peipp, M., Zunino, S.J., Repp, R., Valerius, T. & Fey, G.H. (2004) A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells. British Journal of Haematology, 125, 167179.
  • Bruenke, J., Barbin, K., Kunert, S., Lang, P., Pfeiffer, M., Stieglmaier, K., Niethammer, D., Stockmeyer, B., Peipp, M., Repp, R., Valerius, T. & Fey, G.H. (2005) Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). British Journal Haematology, 130, 218228.
  • Carter, P.J. (2006) Potent antibody therapeutics by design. Nature Reviews. Immunology, 6, 343357.
  • Daeron, M. (1997) Fc receptor biology. Annual Review of Immunology, 15, 203234.
  • Du, X., Ho, M. & Pastan, I. (2007) New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. Journal of Immunotherapy, 30, 607613.
  • Elsasser, D., Valerius, T., Repp, R., Weiner, G.J., Deo, Y., Kalden, J.R., Van De Winkel, J.G., Stevenson, G.T., Glennie, M.J. & Gramatzki, M. (1996) HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood, 87, 38033812.
  • Fleit, H.B., Wright, S.D. & Unkeless, J.C. (1982) Human neutrophil Fc gamma receptor distribution and structure. Proceedings of the National Academy of Sciences of the United States of America, 79, 32753279.
  • Frankel, A.E., Ramage, J., Kiser, M., Alexander, R., Kucera, G. & Miller, M.S. (2000) Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Engineering, 13, 575581.
  • Hauswirth, A.W., Florian, S., Printz, D., Sotlar, K., Krauth, M.T., Fritsch, G., Schernthaner, G.H., Wacheck, V., Selzer, E., Sperr, W.R. & Valent, P. (2007) Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells. European Journal of Clinical Investigation, 37, 7382.
  • Hope, K.J., Jin, L. & Dick, J.E. (2004) Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunology, 5, 738743.
  • Hosen, N., Park, C.Y., Tatsumi, N., Oji, Y., Sugiyama, H., Gramatzki, M., Krensky, A.M. & Weissman, I.L. (2007) CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 104, 1100811013.
  • Huang, S., Chen, Z., Yu, J.F., Young, D., Bashey, A., Ho, A.D. & Law, P. (1999) Correlation between IL-3 receptor expression and growth potential of human CD34+ hematopoietic cells from different tissues. Stem Cells, 17, 265272.
  • Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F. & Dick, J.E. (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Medicine, 12, 11671174.
  • Jin, L., Lee, E.M., Ramshaw, H.S., Busfield, S.J., Peoppl, A.G., Wilkinson, L., Guthridge, M.A., Thomas, D., Barry, E.F., Boyd, A., Gearing, D.P., Vairo, G., Lopez, A.F., Dick, J.E. & Lock, R.B. (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell, 5, 3142.
  • Jordan, C.T., Upchurch, D., Szilvassy, S.J., Guzman, M.L., Howard, D.S., Pettigrew, A.L., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D.A., Luger, S.M. & Phillips, G.L. (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia, 14, 17771784.
  • Kellner, C., Bruenke, J., Stieglmaier, J., Schwemmlein, M., Schwenkert, M., Singer, H., Mentz, K., Peipp, M., Lang, P., Oduncu, F., Stockmeyer, B. & Fey, G.H. (2008) A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. Journal of Immunotherapy, 31, 871884.
  • Kipriyanov, S.M., Cochlovius, B., Schafer, H.J., Moldenhauer, G., Bahre, A., Le Gall, F., Knackmuss, S. & Little, M. (2002) Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin’s lymphoma. Journal of Immunology, 169, 137144.
  • Krebber, A., Bornhauser, S., Burmester, J., Honegger, A., Willuda, J., Bosshard, H.R. & Pluckthun, A. (1997) Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. Journal of Immunological Methods, 201, 3555.
  • Kreitman, R.J., Wilson, W.H., Robbins, D., Margulies, I., Stetler-Stevenson, M., Waldmann, T.A. & Pastan, I. (1999) Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood, 94, 33403348.
  • Kreitman, R.J., Wilson, W.H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D.J. & Pastan, I. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. New England Journal of Medicine, 345, 241247.
  • Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M.A. & Dick, J.E. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645648.
  • Lefebvre, M.L., Krause, S.W., Salcedo, M. & Nardin, A. (2006) Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. Journal of Immunotherapy, 29, 388397.
  • Mirick, G.R., Bradt, B.M., Denardo, S.J. & Denardo, G.L. (2004) A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. The quarterly journal of nuclear medicine and molecular imaging, 48, 251257.
  • Misaghian, N., Ligresti, G., Steelman, L.S., Bertrand, F.E., Basecke, J., Libra, M., Nicoletti, F., Stivala, F., Milella, M., Tafuri, A., Cervello, M., Martelli, A.M. & McCubrey, J.A. (2009) Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia, 23, 2542.
  • Moretti, S., Lanza, F., Dabusti, M., Tieghi, A., Campioni, D., Dominici, M. & Castoldi, G.L. (2001) CD123 (interleukin 3 receptor alpha chain). Journal of Biological Regulators and Homeostatic Agents, 15, 98100.
  • Munoz, L., Nomdedeu, J.F., Lopez, O., Carnicer, M.J., Bellido, M., Aventin, A., Brunet, S. & Sierra, J. (2001) Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica, 86, 12611269.
  • Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., Neri, T.M. & Ardizzoni, A. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. Journal of Clinical Oncology, 26, 17891796.
  • Nagorsen, D., Bargou, R., Ruttinger, D., Kufer, P., Baeuerle, P.A. & Zugmaier, G. (2009) Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leukaemia & Lymphoma, 50, 886891.
  • Onda, M., Nagata, S., FitzGerald, D.J., Beers, R., Fisher, R.J., Vincent, J.J., Lee, B., Nakamura, M., Hwang, J., Kreitman, R.J., Hassan, R. & Pastan, I. (2006) Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. Journal of Immunology, 177, 88228834.
  • Otz, T., Grosse-Hovest, L., Hofmann, M., Rammensee, H.G. & Jung, G. (2009) A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells. Leukemia, 23, 7177.
  • Peipp, M. & Valerius, T. (2002) Bispecific antibodies targeting cancer cells. Biochemical Society Transactions, 30, 507511.
  • Peipp, M., Simon, N., Loichinger, A., Baum, W., Mahr, K., Zunino, S.J. & Fey, G.H. (2001) An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells. Journal of Immunological Methods, 251, 161176.
  • Raghavan, M., Chen, M.Y., Gastinel, L.N. & Bjorkman, P.J. (1994) Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity, 1, 303315.
  • Ravandi, F. & Estrov, Z. (2006) Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clinical Cancer Research, 12, 340344.
  • Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) Molecular Cloning. A Laboratory Manual, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  • Schwemmlein, M., Peipp, M., Barbin, K., Saul, D., Stockmeyer, B., Repp, R., Birkmann, J., Oduncu, F., Emmerich, B. & Fey, G.H. (2006) A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. British Journal of Haematology, 133, 141151.
  • Schwemmlein, M., Stieglmaier, J., Kellner, C., Peipp, M., Saul, D., Oduncu, F., Emmerich, B., Stockmeyer, B., Lang, P., Beck, J.D. & Fey, G.H. (2007) A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. Leukemia, 21, 14051412.
  • Schwenkert, M., Birkholz, K., Schwemmlein, M., Kellner, C., Kugler, M., Peipp, M., Nettelbeck, D.M., Schuler-Thurner, B., Schaft, N., Dorrie, J., Ferrone, S., Kampgen, E. & Fey, G.H. (2008) A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. Melanoma Research, 18, 7384.
  • Sievers, E.L. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opinion on Biological Therapy, 1, 893901.
  • Skerra, A. & Schmidt, T.G. (2000) Use of the Strep-Tag and streptavidin for detection and purification of recombinant proteins. Methods Enzymol, 326, 271304.
  • Sun, Q., Woodcock, J.M., Rapoport, A., Stomski, F.C., Korpelainen, E.I., Bagley, C.J., Goodall, G.J., Smith, W.B., Gamble, J.R., Vadas, M.A. & Lopez, A.F. (1996) Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist. Blood, 87, 8392.
  • Taussig, D.C., Pearce, D.J., Simpson, C., Rohatiner, A.Z., Lister, T.A., Kelly, G., Luongo, J.L., Danet-Desnoyers, G.A. & Bonnet, D. (2005) Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood, 106, 40864092.
  • Tedder, T.F., Baras, A. & Xiu, Y. (2006) Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Seminars in Immunopathology, 28, 351364.
  • Testa, U., Riccioni, R., Diverio, D., Rossini, A., Lo Coco, F. & Peschle, C. (2004) Interleukin-3 receptor in acute leukemia. Leukemia, 18, 219226.
  • Testa, U., Riccioni, R., Biffoni, M., Diverio, D., Lo-Coco, F., Foa, R., Peschle, C. & Frankel, A.E. (2005) Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood, 106, 25272529.
  • Uchida, J., Hamaguchi, Y., Oliver, J.A., Ravetch, J.V., Poe, J.C., Haas, K.M. & Tedder, T.F. (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. Journal of Experimental Medicine, 199, 16591669.
  • Vermes, I., Haanen, C., Steffens-Nakken, H. & Reutelingsperger, C. (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. Journal of Immunological Methods, 184, 3951.
  • Wang, W.W., Das, D., Tang, X.L., Budzynski, W. & Suresh, M.R. (2005) Antigen targeting to dendritic cells with bispecific antibodies. Journal of Immunological Methods, 306, 8092.
  • Weng, W.K. & Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of Clinical Oncology, 21, 39403947.
  • Yvonne, G., Karin, B., Matthias, P., Michael, D., Heike, H., Doreen, T., Roland, R., Georg, F. & Bernhard, S. (2009) A recombinant bispecific single-chain Fv against HLA class II and FcαRI (CD89) efficiently recruits polymorphonuclear neutrophils for lysis of highly resistant malignant B cells. Journal of Immunology, (in press).